H Lundbeck A/S at JPMorgan Healthcare Conference Transcript
Good morning. I'm James Gordon, JP Morgan European Pharma biotech analyst. And today, I've got the pleasure of introducing the Lundbeck presentation. So you're going to hear from Lundbeck's CEO, Deborah Dunsire, and we can have a breakout after this in the Georgian room, and I hope you can join us for that. So with that said, thanks very much for joining us today, and I look forward to the presentation.
/-&
Thanks, James. Good morning, ladies and gentlemen, and it's a pleasure to talk you through 2019 up through the third quarter at Lundbeck and looking out into 2020. You've seen the forward-looking statements, so I won't spend any time there. When we think about Lundbeck, it's a company that has a very strong heritage, bringing forward transformative medicines for brain disease. And we believe that gives us the platform to build towards meeting the still huge unmet medical needs in
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
